HK Stock Market Move | IVD MEDICAL (01931) surged nearly 13% in the afternoon, with a cumulative increase of more than 1.3 times in half a month. Seven strategic actions helped double the company's market value.

IVD MEDICAL (01931) increased by nearly 13% in the afternoon, with a cumulative increase of over 1.3 times in half a month. As of the time of writing, it has increased by 12.78%, reaching 5.12 Hong Kong dollars, with a turnover of 9.5587 million Hong Kong dollars. On the news front, recently, IVD MEDICAL announced a strategic cooperation framework agreement with BGI Genomics, jointly establishing the BGI IVD CoWin Innovation Drug Intellectual Property Tokenization Fund. This fund will invest in projects under the NewCo + RWA Web3 exchange operation model in China, Hong Kong, the United States, or other overseas locations. As a corporate venture capital entity initiated by biotechnology leader BGI Genomics, BGI IVD CoWin has years of experience in domestic and foreign investments and project resources in the fields of Innovative Medical Management and innovative drugs. In "IVD MEDICAL's 'Crazy July,'" it is noted that from announcing the dual major listing in the United States on July 14 to releasing a brand new logo on July 30, the seven major strategic actions propelled IVD MEDICAL's market value from 3.6 billion to nearly 8 billion Hong Kong dollars. Through the cross-border combination of "stablecoin + medical RWA," IVD MEDICAL has positioned itself as a "new species" in the capital markets. Currently, the stablecoin licenses in New York and Hong Kong are still pending, and the listing bell on Nasdaq has not yet rung. IVD MEDICAL's 'Crazy July' is like a strategic surgical strike - using the surgical knife of Web3 to cut through the traditional medical financial veins, turning medical innovation drug assets into on-chain "digital gold."